You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmitriptyline
Accession NumberDB00321  (APRD00227)
TypeSmall Molecule
GroupsApproved
DescriptionAmitriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amitriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, amitriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amitriptyline may be used to treat depression, chronic pain (unlabeled use), irritable bowel syndrome (unlabeled use), diabetic neuropathy (unlabeled use), post-traumatic stress disorder (unlabeled use), and for migraine prophylaxis (unlabeled use).
Structure
Thumb
Synonyms
10,11-dihydro-5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,D)cycloheptene
10,11-dihydro-N,N-Dimethyl-5H-dibenzo(a,D)heptalene-delta(5),gamma-propylamine
3-(10,11-dihydro-5H-Dibenzo(a,D)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine
3-(10,11-dihydro-5H-Dibenzo[a,D]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptatriene
5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,D)cycloheptene
5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,D][1,4]cycloheptadiene
Amitriptilina
Amitriptylin
Amitriptyline
Amitriptylinum
External Identifiers
  • MK 230
  • N 750
  • Ro 4-1575
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amitriptylinetablet25 mgoralSivem Pharmaceuticals Ulc2016-02-11Not applicableCanada
Amitriptylinetablet50 mgoralSivem Pharmaceuticals Ulc2016-02-11Not applicableCanada
Amitriptylinetablet10 mgoralSivem Pharmaceuticals Ulc2016-02-11Not applicableCanada
Amitriptyline 10 Tabtablet10 mgoralDuchesnay Inc1981-12-312003-07-18Canada
Amitriptyline 25 Tabtablet25 mgoralDuchesnay Inc1981-12-312003-07-18Canada
Amitriptyline HCl Tab 25mgtablet25 mgoralD.C. Labs Limited1977-12-312003-07-11Canada
Amitriptyline HCl Tab 50mgtablet50 mgoralD.C. Labs Limited1977-12-312003-07-11Canada
Amitriptyline Tablets B.p 25mgtablet25 mgoralClonmel Healthcare Limited1992-12-311996-09-09Canada
Amitriptyline-10tablet10 mgoralPro Doc Limitee1976-12-31Not applicableCanada
Amitriptyline-25tablet25 mgoralPro Doc Limitee1976-12-31Not applicableCanada
Amitriptyline-50tablet50 mgoralPro Doc Limitee1978-12-31Not applicableCanada
Bio-amitriptylinetablet50 mgoralBiomed Pharma2003-04-23Not applicableCanada
Bio-amitriptylinetablet10 mgoralBiomed Pharma2003-04-23Not applicableCanada
Bio-amitriptylinetablet25 mgoralBiomed Pharma2003-04-23Not applicableCanada
Dom-amitriptylinetablet10 mgoralBiomed Pharma2004-02-062013-08-02Canada
Dom-amitriptylinetablet25 mgoralBiomed Pharma2004-02-062013-08-02Canada
Dom-amitriptylinetablet50 mgoralBiomed Pharma2004-02-062013-08-02Canada
Elaviltablet25 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Elaviltablet75 mgoralAa Pharma Inc1987-12-31Not applicableCanada
Elaviltablet50 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Elaviltablet10 mgoralAa Pharma Inc1975-12-31Not applicableCanada
Elavil Pamoate Syr 10mg/5mlsyrup2 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1968-12-311998-08-14Canada
Elavil Tablet 10mgtablet10 mgoral1560678 Ontario Inc.1961-12-312003-08-02Canada
Elavil Tablet 25mgtablet25 mgoral1560678 Ontario Inc.1961-12-312003-08-02Canada
Elavil Tablet 50mgtablet50 mgoral1560678 Ontario Inc.1964-12-312010-05-05Canada
Elavil Tablet 75mgtablet75 mgoral1560678 Ontario Inc.1976-12-312010-05-05Canada
Ipg-amitriptylinetablet50 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amitriptylinetablet75 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amitriptylinetablet10 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-amitriptylinetablet25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-amitriptyline Tabletstablet75 mgoralJamp Pharma Corporation2015-01-12Not applicableCanada
Jamp-amitriptyline Tabletstablet10 mgoralJamp Pharma Corporation2015-01-12Not applicableCanada
Jamp-amitriptyline Tabletstablet25 mgoralJamp Pharma Corporation2015-01-12Not applicableCanada
Jamp-amitriptyline Tabletstablet50 mgoralJamp Pharma Corporation2015-01-12Not applicableCanada
Levatetablet10 mgoralBiomed Pharma1965-12-31Not applicableCanada
Levatetablet75 mgoralBiomed Pharma1979-12-31Not applicableCanada
Levatetablet25 mgoralBiomed Pharma1974-12-31Not applicableCanada
Levatetablet50 mgoralBiomed Pharma1969-12-31Not applicableCanada
Mar-amitriptylinetablet50 mgoralMarcan Pharmaceuticals Inc2015-04-24Not applicableCanada
Mar-amitriptylinetablet75 mgoralMarcan Pharmaceuticals Inc2015-04-27Not applicableCanada
Mar-amitriptylinetablet10 mgoralMarcan Pharmaceuticals Inc2015-04-24Not applicableCanada
Mar-amitriptylinetablet25 mgoralMarcan Pharmaceuticals Inc2015-04-24Not applicableCanada
Novo-triptyn Tab 10mgtablet10 mgoralNovopharm Limited1972-12-31Not applicableCanada
Novo-triptyn Tab 25mgtablet25 mgoralNovopharm Limited1972-12-31Not applicableCanada
Novo-triptyn Tab 50mgtablet50 mgoralNovopharm Limited1972-12-31Not applicableCanada
Nu-amitriptyline Tabletstablet75 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-amitriptyline Tabletstablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-amitriptyline Tabletstablet25 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-amitriptyline Tabletstablet50 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-amitriptylinetablet50 mgoralBiomed Pharma2003-12-112013-08-02Canada
PMS-amitriptylinetablet10 mgoralBiomed Pharma2003-12-112013-08-02Canada
PMS-amitriptylinetablet25 mgoralBiomed Pharma2003-12-112013-08-02Canada
PMS-amitriptyline Tablets 10mgtablet10 mgoralPharmascience Inc1988-12-31Not applicableCanada
PMS-amitriptyline Tablets 25mgtablet25 mgoralPharmascience Inc1988-12-31Not applicableCanada
PMS-amitriptyline Tablets 50mgtablet50 mgoralPharmascience Inc1988-12-31Not applicableCanada
Teva-amitriptylinetablet10 mgoralTeva Canada Limited2014-12-03Not applicableCanada
Teva-amitriptylinetablet25 mgoralTeva Canada Limited2014-12-03Not applicableCanada
Teva-amitriptylinetablet50 mgoralTeva Canada Limited2014-12-03Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralClinical Solutions Wholesale1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralSandoz Inc1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralC.O. Truxton, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralMylan Institutional Inc.1994-02-16Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralPhysicians Total Care, Inc.1999-09-13Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralTYA Pharmaceuticals1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralAphena Pharma Solutions Tennessee, Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralSTAT Rx USA LLC2009-11-19Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralMedsource Pharmaceuticals2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralUnit Dose Services1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralBlenheim Pharmacal, Inc.2011-10-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralRebel Distributors Corp.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralSTAT Rx USA LLC1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralH.J. Harkins Company, Inc.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralCardinal Health2011-06-17Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralREMEDYREPACK INC.2015-03-07Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralbryant ranch prepack1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralPreferred Pharmaceuticals, Inc.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralSandoz Inc1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralCarilion Materials Management1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2012-09-17Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralMylan Institutional Inc.1994-02-15Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralPhysicians Total Care, Inc.1995-11-07Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralMylan Institutional Inc.1994-12-13Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralPhysicians Total Care, Inc.1995-07-25Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralProficient Rx LP2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralSandoz Inc1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralC.O. Truxton, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralRebel Distributors Corp.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-03-02Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2011-04-18Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralUnit Dose Services1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline Hydrochloridetablet25 mg/1oralDIRECT RX2014-01-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralTYA Pharmaceuticals1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralAphena Pharma Solutions Tennessee, Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet100 mg/1oralREMEDYREPACK INC.2010-12-13Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralSTAT Rx USA LLC1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralH.J. Harkins Company, Inc.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralREMEDYREPACK INC.2015-03-25Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralbryant ranch prepack1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralGLENVIEW PHARMA INC.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralProficient Rx LP2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralBlenheim Pharmacal, Inc.2010-08-04Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-05-31Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.1994-02-16Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralPhysicians Total Care, Inc.1994-10-04Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralClinical Solutions Wholesale1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralLake Erie Medical DBA Quality Care Products LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-24Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralCardinal Health2011-06-17Not applicableUs
Amitriptyline Hydrochloridetablet50 mg/1oralSt. Mary's Medical Park Pharmacy2009-12-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralbryant ranch prepack1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralContract Pharmacy Services Pa2010-02-16Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralPreferred Pharmaceuticals, Inc.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralSandoz Inc1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralRebel Distributors Corp.1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2010-12-16Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralUnit Dose Services1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline Hydrochloridetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralMed Vantx, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralAphena Pharma Solutions Tennessee, Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralGLENVIEW PHARMA INC.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet150 mg/1oralREMEDYREPACK INC.2010-12-13Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralH.J. Harkins Company, Inc.1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralREMEDYREPACK INC.2015-06-02Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralbryant ranch prepack1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralPreferred Pharmaceuticals, Inc.2011-06-09Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralSandoz Inc1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralC.O. Truxton, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralBlenheim Pharmacal, Inc.2010-03-03Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-10-31Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralMylan Institutional Inc.1994-10-26Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralPhysicians Total Care, Inc.2003-02-04Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralClinical Solutions Wholesale1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralProficient Rx LP1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralRebel Distributors Corp.1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralSTAT Rx USA LLC1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralREMEDYREPACK INC.2013-10-15Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralCardinal Health2011-06-17Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Amitriptyline Hydrochloridetablet25 mg/1oralbryant ranch prepack2009-10-23Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralSandoz Inc1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralMylan Pharmaceuticals Inc.1978-04-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralAccord Healthcare Inc.2014-12-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralAidarex Pharmaceuticals LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet100 mg/1oralREMEDYREPACK INC.2011-12-06Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralUnit Dose Services1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralPhysicians Total Care, Inc.1996-06-18Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralDIRECT RX2015-01-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated25 mg/1oralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralDispensing Solutions, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated100 mg/1oralContract Pharmacy Services Pa1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralGLENVIEW PHARMA INC.1977-11-29Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralNorthstar Rx LLC2014-12-01Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralQualitest Pharmaceuticals1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralSTAT Rx USA LLC1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2010-12-13Not applicableUs
Amitriptyline Hydrochloridetablet, film coated75 mg/1oralPd Rx Pharmaceuticals, Inc.1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralUnit Dose Services1977-11-21Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralA S Medication Solutions Llc1997-09-11Not applicableUs
Amitriptyline Hydrochloridetablet, film coated10 mg/1oralSun Pharmaceutical Industries, Inc.1987-07-14Not applicableUs
Amitriptyline Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2015-06-05Not applicableUs
Amitriptyline Hydrochloridetablet, film coated150 mg/1oralbryant ranch prepack1997-09-11Not applicableUs
Apo-amitriptylinetablet75 mgoralApotex Inc2013-06-12Not applicableCanada
Apo-amitriptylinetablet10 mgoralApotex Inc2013-06-12Not applicableCanada
Apo-amitriptylinetablet25 mgoralApotex Inc2013-06-12Not applicableCanada
Apo-amitriptylinetablet50 mgoralApotex Inc2013-06-12Not applicableCanada
Elavil 25 mgtablet25 mg/1oralThompson Medical Solutions Llc1997-09-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Equipto - Amitriptyline External Cream Compounding KitkittopicalAlvix Laboratories, LLC2015-01-20Not applicableUs
International Brands
NameCompany
AdeprilTeofarma
AmitrypRaza
ConmitripCondrugs
EndepAlphapharm
FiordaDriburg
KamitrinSaga
LaroxylDeva
LatilinLa Pharmaceuticals
MaxitripInvision
RedomexLundbeck
SarotenLundbeck
SarotexLundbeck
Sarotex RetardLundbeck
SyneudonKrewel Meuselbach
TryptanolMerck Sharp & Dohme
TryptanolSquare
TryptizolAlgorithm
Uxen RetardSanofi-Aventis
Brand mixtures
NameLabellerIngredients
Apo Peram Tab 2-25Apotex Inc
Apo Peram Tab 3-15Apotex Inc
Chlordiazepoxide and Amitriptyline HClPar Pharmaceutical Inc
Chlordiazepoxide and Amitriptyline HydrochlorideMylan Pharmaceuticals Inc.
Elavil Plus TabTriton Pharma Inc
Etrafon 2 10Schering Plough Canada Inc
Etrafon A TabSchering Plough Canada Inc
Etrafon D TabSchering Plough Canada Inc
Etrafon F TabSchering Plough Canada Inc
Perphenazine and Amitriptyline HydrochlorideMylan Pharmaceuticals Inc.
PMS-levazine 2/25 TabPharmascience Inc
PMS-levazine 3/15 TabPharmascience Inc
PMS-levazine 4/25 TabPharmascience Inc
Proavil TabPro Doc Limitee
Sentravil PM-25Physician Therapeutics Llc
Triavil TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Salts
Name/CASStructureProperties
Amitriptyline Hydrochloride
Thumb
  • InChI Key: KFYRPLNVJVHZGT-UHFFFAOYSA-N
  • Monoisotopic Mass: 313.15972748
  • Average Mass: 313.864
DBSALT000009
Amitriptyline Pamoate
ThumbNot applicableDBSALT001193
Categories
UNII1806D8D52K
CAS number50-48-6
WeightAverage: 277.4033
Monoisotopic: 277.183049741
Chemical FormulaC20H23N
InChI KeyInChIKey=KRMDCWKBEZIMAB-UHFFFAOYSA-N
InChI
InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
IUPAC Name
dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine
SMILES
CN(C)CCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene connected by a cycloheptene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassDibenzocycloheptenes
Sub ClassNot Available
Direct ParentDibenzocycloheptenes
Alternative Parents
Substituents
  • Dibenzocycloheptene
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of depression, chronic pain, irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia, and migraine prophylaxis.
PharmacodynamicsAmitriptyline, a tertiary amine tricyclic antidepressant, is structurally related to both the skeletal muscle relaxant cyclobenzaprine and the thioxanthene antipsychotics such as thiothixene. It is extremely sedating, and thus improvement of sleep patterns can be the first benefit of treatment. Amitriptyline exhibits strong anticholinergic activity, cardiovascular effects including orthostatic hypotension, changes in heart rhythm and conduction, and a lowering of the seizure threshold. As with other antidepressants, several weeks of therapy may be required in order to realize the full clinical benefit of amitriptyline. Although not a labelled indication, amitriptyline is widely used in the management of chronic nonmalignant pain (e.g., post-herpetic neuralgia, fibromyalgia).
Mechanism of actionAmitriptyline is metabolized to nortriptyline which inhibits the reuptake of norepinephrine and serotonin almost equally. Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. Pharmacologically this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity. This interference with the reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.
Related Articles
AbsorptionRapidly and well absorbed following oral administration (bioavailability is 30-60% due to first pass metabolism). Peak plasma concentrations occur 2-12 hours following oral or intramuscular administration.
Volume of distributionNot Available
Protein bindingVery highly protein bound (90% or more) in plasma and tissues
Metabolism

Exclusively hepatic, with first pass effect. Amitriptyline is demethylated in the liver to its primary active metabolite, nortriptyline.

SubstrateEnzymesProduct
Amitriptyline
NortriptylineDetails
Amitriptyline
E-10-HydroxyamitriptylineDetails
E-10-Hydroxyamitriptyline
E-10-HydroxynortriptylineDetails
E-10-Hydroxynortriptyline
Not Available
E-10-HydroxydesmethylnortriptylineDetails
Nortriptyline
E-10-HydroxynortriptylineDetails
Nortriptyline
Not Available
DesmethylnortriptylineDetails
Desmethylnortriptyline
E-10-HydroxydesmethylnortriptylineDetails
Route of eliminationVirtually the entire dose is excreted as glucuronide or sulfate conjugate of metabolites, with little unchanged drug appearing in the urine. 25-50% of a single orally administered dose is excreted in urine as inactive metabolites within 24 hours. Small amounts are excreted in feces via biliary elimination.
Half life10 to 50 hours, with an average of 15 hours
ClearanceNot Available
ToxicityLD50=350 mg/kg (in mice). Symptoms of overdose include abnormally low blood pressure, confusion, convulsions, dilated pupils and other eye problems, disturbed concentration, drowsiness, hallucinations, impaired heart function, rapid or irregular heartbeat, reduced body temperature, stupor, and unresponsiveness or coma. Side effects include: sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A AllelePoor drug metabolizer, lower dose requirements, higher risk for adverse side effects18070221
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableA > GIncrease risk of adverse effects22641028
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs1045642 Not AvailableT Allele, homozygousPostural hypotension12082591
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2G > AThose with the AA or AG genotype are poor metabolizers of amitriptyline20531370
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TIncrease risk of side effects and decrease drug metabolism18070221
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4C > TIncrease risk of side effects and decrease drug metabolism9918137
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9512
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7567
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6447
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7501
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9158
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6955
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8127
BiodegradationNot ready biodegradable0.8727
Rat acute toxicity2.9697 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.6767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Watson laboratories inc
  • Astrazeneca pharmaceuticals lp
  • Bristol myers squibb co
  • Warner chilcott div warner lambert co
  • American therapeutics inc
  • Caraco pharmaceutical laboratories ltd
  • Copley pharmaceutical inc
  • Halsey drug co inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Ucb inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral100 mg/1
Tabletoral150 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral150 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral75 mg/1
Syruporal2 mg
Kittopical
Tabletoral75 mg
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Tabletoral
Tablet, film coatedoral
Kit
Prices
Unit descriptionCostUnit
Amitriptyline hcl powder7.34USD g
Amitriptyline hcl 150 mg tablet1.18USD tablet
Amitriptyline hcl 100 mg tablet0.66USD tablet
Amitriptyline hcl 75 mg tablet0.54USD tablet
Apo-Amitriptyline 75 mg Tablet0.38USD tablet
Amitriptyline hcl 50 mg tablet0.37USD tablet
Amitriptyline hcl 10 mg tablet0.3USD tablet
Apo-Amitriptyline 50 mg Tablet0.25USD tablet
Amitriptyline hcl 25 mg tablet0.21USD tablet
Apo-Amitriptyline 25 mg Tablet0.13USD tablet
Apo-Amitriptyline 10 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point187-189.5Tristram, E.W. and Tull, R.J.; US. Patent 3,205,264: September 7,1965; assigned to Merck & Co., Inc.
water solubility9.71 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.92HANSCH,C ET AL. (1995)
logS-4.46ADME Research, USCD
pKa9.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP5.1ALOGPS
logP4.81ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity101.51 m3·mol-1ChemAxon
Polarizability33.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.48 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9210000000-989cd234a8cdf04c5f69View in MoNA
References
Synthesis Reference

Manfred Durr, Benedikt Gajdos, Klaus-Dieter Gneuss, Ekkehard Harhausen, Jurgen Seidel, “Pharmaceutical amitriptylin oxide preparation and process for its manufacture.” U.S. Patent US4567202, issued January 28, 1986.

US4567202
General References
  1. Otaka M, Jin M, Odashima M, Matsuhashi T, Wada I, Horikawa Y, Komatsu K, Ohba R, Oyake J, Hatakeyama N, Watanabe S: New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther. 2005 Jun;21 Suppl 2:42-6. [PubMed:15943846 ]
External Links
ATC CodesN06AA09N06CA01
AHFS Codes
  • 28:16.04.28
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Amitriptyline can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Amitriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-MethylenedioxyamphetamineAmitriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineAmitriptyline may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Amitriptyline can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Amitriptyline.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amitriptyline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Amitriptyline.
AbirateroneThe serum concentration of Amitriptyline can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Amitriptyline.
AcenocoumarolAmitriptyline may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Aceprometazine.
AcetaminophenThe serum concentration of Amitriptyline can be increased when it is combined with Acetaminophen.
AcetophenazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Acetophenazine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Amitriptyline.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Amitriptyline.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Amitriptyline.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Amitriptyline.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amitriptyline.
AlbendazoleThe serum concentration of Amitriptyline can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Amitriptyline can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Amitriptyline.
AlectinibThe serum concentration of Amitriptyline can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Amitriptyline.
AlfentanilThe serum concentration of Amitriptyline can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Amitriptyline.
AlmotriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Almotriptan.
AlogliptinThe serum concentration of Amitriptyline can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Amitriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amitriptyline.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amitriptyline.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Amitriptyline.
AmantadineThe serum concentration of Amitriptyline can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Amitriptyline.
Aminohippuric acidThe serum concentration of Amitriptyline can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Amitriptyline can be decreased when it is combined with Amiodarone.
AmiodaroneAmitriptyline may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Amisulpride.
AmlodipineThe serum concentration of Amitriptyline can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amitriptyline.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Amitriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Amperozide.
AmphetamineAmitriptyline may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Amitriptyline can be increased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Amitriptyline can be increased when it is combined with Amsacrine.
AnagrelideAmitriptyline may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III humanThe serum concentration of Amitriptyline can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Amitriptyline can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Amitriptyline.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Amitriptyline.
AprepitantThe serum concentration of Amitriptyline can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Amitriptyline can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Arformoterol.
ArgatrobanThe serum concentration of Amitriptyline can be increased when it is combined with Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Amitriptyline.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amitriptyline.
ArmodafinilThe metabolism of Amitriptyline can be decreased when combined with Armodafinil.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Amitriptyline.
ArtemetherAmitriptyline may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Amitriptyline can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Amitriptyline.
AsenapineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Asenapine.
AstemizoleThe serum concentration of Amitriptyline can be increased when it is combined with Astemizole.
AsunaprevirThe serum concentration of Amitriptyline can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Amitriptyline can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Amitriptyline can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Amitriptyline can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Amitriptyline can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amitriptyline.
AzaperoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Azaperone.
AzelastineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Amitriptyline can be increased when it is combined with Azelastine.
AzithromycinAmitriptyline may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Amitriptyline can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Amitriptyline.
BambuterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Bambuterol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Amitriptyline.
BatimastatThe serum concentration of Amitriptyline can be increased when it is combined with Batimastat.
BedaquilineAmitriptyline may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Amitriptyline can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the serotonergic activities of Amitriptyline.
BenzamidineThe serum concentration of Amitriptyline can be increased when it is combined with Benzamidine.
BenzocaineThe serum concentration of Amitriptyline can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Benzocaine.
BenzphetamineAmitriptyline may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amitriptyline.
BepridilThe serum concentration of Amitriptyline can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Amitriptyline.
BetaxololThe metabolism of Amitriptyline can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Amitriptyline.
BexaroteneThe serum concentration of Amitriptyline can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Bifeprunox.
BiperidenThe serum concentration of Amitriptyline can be increased when it is combined with Biperiden.
BivalirudinThe serum concentration of Amitriptyline can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Amitriptyline can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Amitriptyline can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Amitriptyline can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amitriptyline.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amitriptyline.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Amitriptyline.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amitriptyline.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amitriptyline.
BromocriptineThe serum concentration of Amitriptyline can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Amitriptyline.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amitriptyline.
BuprenorphineThe serum concentration of Amitriptyline can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Buprenorphine.
BupropionThe metabolism of Amitriptyline can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Amitriptyline can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amitriptyline.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Amitriptyline.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Amitriptyline.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Amitriptyline.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amitriptyline.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amitriptyline.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Amitriptyline.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amitriptyline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Amitriptyline.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Amitriptyline.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Amitriptyline.
CandesartanThe serum concentration of Amitriptyline can be increased when it is combined with Candesartan.
CandoxatrilThe serum concentration of Amitriptyline can be increased when it is combined with Candoxatril.
CapecitabineThe metabolism of Amitriptyline can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Amitriptyline can be increased when it is combined with Captopril.
CarbamazepineThe metabolism of Amitriptyline can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Amitriptyline.
CarbinoxamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amitriptyline.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Amitriptyline.
CariprazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Carisoprodol.
CaroxazoneCaroxazone may increase the serotonergic activities of Amitriptyline.
CarvedilolThe serum concentration of Amitriptyline can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Amitriptyline can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Amitriptyline can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Celiprolol.
CeritinibThe serum concentration of Amitriptyline can be increased when it is combined with Ceritinib.
CeritinibAmitriptyline may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Amitriptyline.
CetirizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amitriptyline.
ChloramphenicolThe metabolism of Amitriptyline can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amitriptyline.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amitriptyline.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amitriptyline.
ChloroquineAmitriptyline may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Amitriptyline can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorphenamine.
ChlorphentermineAmitriptyline may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorpromazine.
ChlorpromazineThe serum concentration of Amitriptyline can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Amitriptyline can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorprothixene.
ChlorprothixeneThe serum concentration of Amitriptyline can be increased when it is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Amitriptyline can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Amitriptyline can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Amitriptyline can be decreased when it is combined with Cholic Acid.
ChymostatinThe serum concentration of Amitriptyline can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Amitriptyline can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Amitriptyline can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Amitriptyline.
CimetidineThe metabolism of Amitriptyline can be decreased when combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Amitriptyline.
CinacalcetThe serum concentration of Amitriptyline can be increased when it is combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amitriptyline.
CiprofloxacinAmitriptyline may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Amitriptyline can be increased when it is combined with Ciprofloxacin.
CirazolineAmitriptyline may increase the vasopressor activities of Cirazoline.
CisaprideAmitriptyline may increase the arrhythmogenic activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Amitriptyline.
CitalopramThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Citalopram.
CitalopramThe serum concentration of Amitriptyline can be increased when it is combined with Citalopram.
ClarithromycinAmitriptyline may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Amitriptyline can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Amitriptyline can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clenbuterol.
ClidiniumThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Amitriptyline.
ClobazamThe metabolism of Amitriptyline can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Amitriptyline can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Amitriptyline.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Amitriptyline.
ClomipramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clomipramine.
ClomipramineThe serum concentration of Amitriptyline can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clonazepam.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Amitriptyline.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Amitriptyline.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Amitriptyline.
ClopidogrelThe metabolism of Amitriptyline can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amitriptyline.
ClotrimazoleThe metabolism of Amitriptyline can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Clozapine.
ClozapineThe metabolism of Amitriptyline can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Amitriptyline can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amitriptyline.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amitriptyline.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amitriptyline.
ColchicineThe serum concentration of Amitriptyline can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Amitriptyline can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Amitriptyline can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Amitriptyline.
CrizotinibAmitriptyline may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Amitriptyline can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amitriptyline.
CyclophosphamideThe serum concentration of Amitriptyline can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Amitriptyline can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Amitriptyline.
CyproheptadineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Amitriptyline can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Amitriptyline can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Amitriptyline can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Amitriptyline.
DaclatasvirThe serum concentration of Amitriptyline can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Amitriptyline can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Amitriptyline.
DapiprazoleThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amitriptyline.
DarifenacinThe metabolism of Amitriptyline can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Amitriptyline can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Amitriptyline can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Amitriptyline can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Amitriptyline.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Amitriptyline.
DeferasiroxThe serum concentration of Amitriptyline can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Amitriptyline can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Amitriptyline.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amitriptyline.
DesipramineThe serum concentration of Amitriptyline can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desipramine.
DesloratadineThe serum concentration of Amitriptyline can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Amitriptyline.
DexamethasoneThe serum concentration of Amitriptyline can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Amitriptyline.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dexbrompheniramine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Amitriptyline.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amitriptyline.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Amitriptyline.
DextroamphetamineAmitriptyline may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe serum concentration of Amitriptyline can be increased when it is combined with Dextromethorphan.
DextromethorphanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amitriptyline.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amitriptyline.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amitriptyline.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Amitriptyline.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amitriptyline.
DiclofenacThe serum concentration of Amitriptyline can be increased when it is combined with Diclofenac.
DicoumarolAmitriptyline may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Amitriptyline.
DifenoxinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Amitriptyline.
DigoxinThe serum concentration of Amitriptyline can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Amitriptyline.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amitriptyline.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Amitriptyline.
DihydroergotamineThe metabolism of Amitriptyline can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amitriptyline.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amitriptyline.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Amitriptyline.
DiltiazemThe metabolism of Amitriptyline can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Amitriptyline.
DimenhydrinateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Amitriptyline can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amitriptyline.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Amitriptyline.
DipyridamoleThe serum concentration of Amitriptyline can be increased when it is combined with Dipyridamole.
DisopyramideAmitriptyline may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Amitriptyline can be decreased when combined with Disulfiram.
DobutamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dobutamine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Amitriptyline.
DofetilideAmitriptyline may increase the QTc-prolonging activities of Dofetilide.
DolasetronAmitriptyline may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Amitriptyline.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Amitriptyline.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Amitriptyline.
DoxazosinThe serum concentration of Amitriptyline can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Amitriptyline can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Doxepin.
DoxorubicinThe serum concentration of Amitriptyline can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amitriptyline.
DoxycyclineThe metabolism of Amitriptyline can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
DoxylamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Amitriptyline.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
DronedaroneThe metabolism of Amitriptyline can be decreased when combined with Dronedarone.
DronedaroneAmitriptyline may increase the QTc-prolonging activities of Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amitriptyline.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Amitriptyline.
DuloxetineThe metabolism of Amitriptyline can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amitriptyline.
EcabetThe serum concentration of Amitriptyline can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amitriptyline.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Amitriptyline.
EdoxabanThe serum concentration of Amitriptyline can be increased when it is combined with Edoxaban.
EfavirenzThe serum concentration of Amitriptyline can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Efavirenz.
ElafinThe serum concentration of Amitriptyline can be increased when it is combined with Elafin.
ElbasvirThe serum concentration of Amitriptyline can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Amitriptyline.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amitriptyline.
EliglustatAmitriptyline may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Amitriptyline can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Amitriptyline can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Amitriptyline can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Amitriptyline can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amitriptyline.
EntacaponeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Entacapone.
EnzalutamideThe serum concentration of Amitriptyline can be increased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Amitriptyline.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Amitriptyline.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Amitriptyline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergoloid mesylate.
ErgonovineThe serum concentration of Amitriptyline can be increased when it is combined with Ergonovine.
ErgonovineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergonovine.
ErgotamineAmitriptyline may increase the vasopressor activities of Ergotamine.
ErgotamineThe serum concentration of Amitriptyline can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Amitriptyline.
ErythromycinAmitriptyline may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Amitriptyline can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Amitriptyline can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Amitriptyline can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amitriptyline.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Amitriptyline.
EstramustineThe serum concentration of Amitriptyline can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Amitriptyline can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Amitriptyline.
EstroneThe serum concentration of Amitriptyline can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Amitriptyline.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amitriptyline.
EthanolAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Amitriptyline.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptyline.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Amitriptyline.
EthosuximideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethotoin.
Ethyl biscoumacetateAmitriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amitriptyline.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amitriptyline.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amitriptyline.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Amitriptyline.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Amitriptyline.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Amitriptyline.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Amitriptyline.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amitriptyline.
EtoperidoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Etoperidone.
EtoposideThe serum concentration of Amitriptyline can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amitriptyline.
EtravirineThe serum concentration of Amitriptyline can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amitriptyline.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Amitriptyline.
EzogabineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Felbamate.
FelodipineThe serum concentration of Amitriptyline can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fenoterol.
FentanylThe serum concentration of Amitriptyline can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amitriptyline.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Amitriptyline.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Amitriptyline.
FlecainideAmitriptyline may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flibanserin.
FloxuridineThe metabolism of Amitriptyline can be decreased when combined with Floxuridine.
FluconazoleAmitriptyline may increase the QTc-prolonging activities of Fluconazole.
FluconazoleThe metabolism of Amitriptyline can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amitriptyline.
FlunarizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amitriptyline.
FluorouracilThe metabolism of Amitriptyline can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluoxetine.
FluoxetineThe serum concentration of Amitriptyline can be increased when it is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flupentixol.
FlupentixolThe serum concentration of Amitriptyline can be increased when it is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluphenazine.
FluphenazineThe serum concentration of Amitriptyline can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Amitriptyline can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Amitriptyline.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Amitriptyline can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fluvoxamine.
FluvoxamineThe metabolism of Amitriptyline can be decreased when combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Formoterol.
FosamprenavirThe serum concentration of Amitriptyline can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Amitriptyline can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Amitriptyline can be increased when it is combined with Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amitriptyline.
FrovatriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the serotonergic activities of Amitriptyline.
Fusidic AcidThe serum concentration of Amitriptyline can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amitriptyline.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Amitriptyline is combined with gabapentin enacarbil.
Gadobenic acidAmitriptyline may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amitriptyline.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Amitriptyline.
GeldanamycinThe serum concentration of Amitriptyline can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Amitriptyline.
GemfibrozilThe metabolism of Amitriptyline can be decreased when combined with Gemfibrozil.
GemifloxacinAmitriptyline may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Amitriptyline can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amitriptyline.
GlyburideThe serum concentration of Amitriptyline can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Amitriptyline can be increased when it is combined with Glycerol.
GM6001The serum concentration of Amitriptyline can be increased when it is combined with GM6001.
GoserelinAmitriptyline may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Amitriptyline can be increased when it is combined with Gramicidin D.
GranisetronAmitriptyline may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Amitriptyline.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Amitriptyline.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Amitriptyline.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Amitriptyline.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Amitriptyline.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Amitriptyline.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amitriptyline.
HaloperidolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Haloperidol.
HaloperidolThe serum concentration of Amitriptyline can be increased when it is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amitriptyline.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amitriptyline.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amitriptyline.
HirulogThe serum concentration of Amitriptyline can be increased when it is combined with Hirulog.
HydracarbazineHydracarbazine may increase the serotonergic activities of Amitriptyline.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amitriptyline.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Amitriptyline.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amitriptyline.
Hydroxyamphetamine hydrobromideAmitriptyline may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
HydroxyzineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Amitriptyline.
IbutilideAmitriptyline may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Amitriptyline can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Iloperidone.
ImatinibThe metabolism of Amitriptyline can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Amitriptyline.
ImipramineThe serum concentration of Amitriptyline can be increased when it is combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Indalpine.
IndinavirThe serum concentration of Amitriptyline can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Amitriptyline can be increased when it is combined with Indomethacin.
IproclozideIproclozide may increase the serotonergic activities of Amitriptyline.
IproniazidIproniazid may increase the serotonergic activities of Amitriptyline.
IrbesartanThe metabolism of Amitriptyline can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Amitriptyline.
IsavuconazoniumThe metabolism of Amitriptyline can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Amitriptyline.
IsocarboxazidThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isoetarine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amitriptyline.
IsoflurophateThe serum concentration of Amitriptyline can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Amitriptyline can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Isoprenaline.
IsradipineThe metabolism of Amitriptyline can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Amitriptyline can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Amitriptyline can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Amitriptyline.
IxazomibThe serum concentration of Amitriptyline can be increased when it is combined with Ixazomib.
KetamineThe serum concentration of Amitriptyline can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Amitriptyline.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amitriptyline.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amitriptyline.
KetoconazoleThe serum concentration of Amitriptyline can be increased when it is combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Amitriptyline.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Amitriptyline.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Amitriptyline.
LansoprazoleThe serum concentration of Amitriptyline can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Amitriptyline can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Amitriptyline.
LeflunomideThe metabolism of Amitriptyline can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Amitriptyline.
LenvatinibAmitriptyline may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Amitriptyline can be increased when it is combined with Lepirudin.
LeuprolideAmitriptyline may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Amitriptyline.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Amitriptyline.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amitriptyline.
LevocabastineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levodopa.
LevofloxacinAmitriptyline may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Amitriptyline can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amitriptyline.
LevomilnacipranThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amitriptyline.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Amitriptyline.
LidocaineThe serum concentration of Amitriptyline can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lidocaine.
LinagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Amitriptyline.
LinezolidThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Amitriptyline.
LiotrixLiotrix may increase the arrhythmogenic activities of Amitriptyline.
LisdexamfetamineAmitriptyline may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Amitriptyline can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Amitriptyline.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Amitriptyline.
LomitapideThe serum concentration of Amitriptyline can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Amitriptyline can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Amitriptyline can be increased when it is combined with Lopinavir.
LopinavirAmitriptyline may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Amitriptyline can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amitriptyline.
LorcaserinThe metabolism of Amitriptyline can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lorcaserin.
LosartanThe serum concentration of Amitriptyline can be increased when it is combined with Losartan.
LovastatinThe metabolism of Amitriptyline can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Amitriptyline is combined with Lu AA21004.
LuliconazoleThe serum concentration of Amitriptyline can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Amitriptyline can be decreased when it is combined with Lumacaftor.
LumefantrineAmitriptyline may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Amitriptyline can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Amitriptyline.
MaprotilineThe serum concentration of Amitriptyline can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Maprotiline.
MebanazineMebanazine may increase the serotonergic activities of Amitriptyline.
MebendazoleThe serum concentration of Amitriptyline can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Amitriptyline.
MefloquineThe serum concentration of Amitriptyline can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Amitriptyline can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amitriptyline.
MelperoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Melperone.
MephentermineAmitriptyline may increase the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amitriptyline.
MeprobamateThe serum concentration of Amitriptyline can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Mesoridazine.
MetaraminolAmitriptyline may increase the vasopressor activities of Metaraminol.
MetaxaloneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Metaxalone.
MethadoneAmitriptyline may increase the QTc-prolonging activities of Methadone.
MethadoneThe serum concentration of Amitriptyline can be increased when it is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amitriptyline.
MethamphetamineAmitriptyline may increase the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amitriptyline.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amitriptyline.
MethocarbamolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amitriptyline.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Amitriptyline.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methotrimeprazine.
MethoxamineAmitriptyline may increase the vasopressor activities of Methoxamine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amitriptyline.
MethsuximideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methsuximide.
Methylene blueAmitriptyline may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amitriptyline.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Amitriptyline.
MetoclopramideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Metoclopramide.
MetoprololThe serum concentration of Amitriptyline can be increased when it is combined with Metoprolol.
MetyrosineAmitriptyline may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amitriptyline.
MexiletineThe metabolism of Amitriptyline can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Amitriptyline can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Amitriptyline can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Amitriptyline can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Amitriptyline.
MidodrineAmitriptyline may increase the vasopressor activities of Midodrine.
MifepristoneThe metabolism of Amitriptyline can be decreased when combined with Mifepristone.
MifepristoneAmitriptyline may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Amitriptyline.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Amitriptyline.
MirabegronThe metabolism of Amitriptyline can be decreased when combined with Mirabegron.
MirtazapineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amitriptyline.
MitomycinThe serum concentration of Amitriptyline can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Amitriptyline can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Amitriptyline can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Amitriptyline.
MoclobemideMoclobemide may increase the serotonergic activities of Amitriptyline.
MoclobemideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Moclobemide.
ModafinilThe serum concentration of Amitriptyline can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Amitriptyline can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Amitriptyline.
MoxifloxacinAmitriptyline may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Amitriptyline.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amitriptyline.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Amitriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
NabiloneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Amitriptyline.
NafcillinThe serum concentration of Amitriptyline can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amitriptyline.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amitriptyline.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Amitriptyline.
NaltrexoneThe serum concentration of Amitriptyline can be increased when it is combined with Naltrexone.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Amitriptyline.
NaratriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Naratriptan.
NaringeninThe serum concentration of Amitriptyline can be increased when it is combined with Naringenin.
NCX 4016The serum concentration of Amitriptyline can be increased when it is combined with NCX 4016.
NefazodoneThe serum concentration of Amitriptyline can be decreased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nefazodone.
NelfinavirThe serum concentration of Amitriptyline can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Amitriptyline can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Amitriptyline can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Amitriptyline can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Amitriptyline.
NicardipineThe serum concentration of Amitriptyline can be increased when it is combined with Nicardipine.
NicorandilAmitriptyline may increase the hypotensive activities of Nicorandil.
NicotineThe metabolism of Amitriptyline can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Amitriptyline can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Amitriptyline.
NilotinibThe metabolism of Amitriptyline can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Amitriptyline.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amitriptyline.
NisoldipineThe serum concentration of Amitriptyline can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Amitriptyline can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nitrazepam.
NitrendipineThe serum concentration of Amitriptyline can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Amitriptyline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Amitriptyline.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Amitriptyline.
NorethisteroneThe serum concentration of Amitriptyline can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Amitriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Nortriptyline.
OctamoxinOctamoxin may increase the serotonergic activities of Amitriptyline.
OfloxacinAmitriptyline may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olanzapine.
OlaparibThe metabolism of Amitriptyline can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olodaterol.
OlopatadineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Olopatadine.
OmapatrilatThe serum concentration of Amitriptyline can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Amitriptyline.
OmeprazoleThe serum concentration of Amitriptyline can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Amitriptyline.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Amitriptyline.
OrciprenalineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Orciprenaline.
OrphenadrineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Amitriptyline.
OsanetantThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Osanetant.
OsimertinibThe serum concentration of Amitriptyline can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Amitriptyline can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amitriptyline.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amitriptyline.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amitriptyline.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amitriptyline.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Amitriptyline.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amitriptyline.
P-NitrophenolThe serum concentration of Amitriptyline can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Amitriptyline can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Amitriptyline can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Amitriptyline.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amitriptyline.
Palmitic AcidThe serum concentration of Amitriptyline can be increased when it is combined with Palmitic Acid.
PalonosetronPalonosetron may increase the serotonergic activities of Amitriptyline.
PanobinostatAmitriptyline may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Amitriptyline can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Amitriptyline can be increased when it is combined with Pantoprazole.
ParaldehydeAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Amitriptyline.
PargylinePargyline may increase the serotonergic activities of Amitriptyline.
ParoxetineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Paroxetine.
ParoxetineThe serum concentration of Amitriptyline can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amitriptyline.
Peginterferon alfa-2bThe serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineAmitriptyline may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amitriptyline.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amitriptyline.
PerampanelThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Perampanel.
PerflutrenAmitriptyline may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Amitriptyline.
PerindoprilThe serum concentration of Amitriptyline can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amitriptyline.
PhenelzinePhenelzine may increase the serotonergic activities of Amitriptyline.
PhenelzineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Phenelzine.
PhenindioneAmitriptyline may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Amitriptyline.
PhenobarbitalThe serum concentration of Amitriptyline can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Amitriptyline.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Amitriptyline.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Amitriptyline.
PhenprocoumonAmitriptyline may increase the anticoagulant activities of Phenprocoumon.
PhentermineAmitriptyline may increase the stimulatory activities of Phentermine.
PhenylephrineAmitriptyline may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Amitriptyline.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Amitriptyline.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Amitriptyline.
PhosphoramidonThe serum concentration of Amitriptyline can be increased when it is combined with Phosphoramidon.
PimozideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pimozide.
PimozideThe serum concentration of Amitriptyline can be increased when it is combined with Pimozide.
PioglitazoneThe metabolism of Amitriptyline can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pirbuterol.
PirlindolePirlindole may increase the serotonergic activities of Amitriptyline.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Amitriptyline.
PivhydrazinePivhydrazine may increase the serotonergic activities of Amitriptyline.
PizotifenThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Amitriptyline can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Amitriptyline.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Amitriptyline.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Amitriptyline.
PosaconazoleThe serum concentration of Amitriptyline can be increased when it is combined with Posaconazole.
PramipexoleAmitriptyline may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Amitriptyline.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Amitriptyline.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amitriptyline.
PrazosinThe serum concentration of Amitriptyline can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amitriptyline.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amitriptyline.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amitriptyline.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amitriptyline.
PrimaquineAmitriptyline may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Primidone.
PrinomastatThe serum concentration of Amitriptyline can be increased when it is combined with Prinomastat.
ProbenecidThe serum concentration of Amitriptyline can be increased when it is combined with Probenecid.
ProcainamideAmitriptyline may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amitriptyline.
ProcarbazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Procaterol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Prochlorperazine.
ProgesteroneThe serum concentration of Amitriptyline can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Amitriptyline.
PromazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Promazine.
PromazineThe metabolism of Amitriptyline can be decreased when combined with Promazine.
PromethazineThe serum concentration of Amitriptyline can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Promethazine.
PropafenoneAmitriptyline may increase the QTc-prolonging activities of Propafenone.
PropafenoneThe serum concentration of Amitriptyline can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amitriptyline.
PropericiazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amitriptyline.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Amitriptyline.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Amitriptyline.
ProtriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amitriptyline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Amitriptyline.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Amitriptyline.
PyrimethamineThe metabolism of Amitriptyline can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Amitriptyline can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Quazepam.
QuercetinThe serum concentration of Amitriptyline can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Quetiapine.
QuinacrineThe serum concentration of Amitriptyline can be increased when it is combined with Quinacrine.
QuinaprilThe serum concentration of Amitriptyline can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Amitriptyline can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Amitriptyline can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Amitriptyline can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ramelteon.
RamiprilThe serum concentration of Amitriptyline can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Amitriptyline can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amitriptyline.
RasagilineRasagiline may increase the serotonergic activities of Amitriptyline.
RasagilineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Rasagiline.
ReboxetineThe serum concentration of Amitriptyline can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Amitriptyline can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amitriptyline.
RemikirenThe serum concentration of Amitriptyline can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Reserpine.
ReserpineThe serum concentration of Amitriptyline can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Amitriptyline can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Amitriptyline can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Amitriptyline.
RifapentineThe metabolism of Amitriptyline can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amitriptyline.
RilpivirineThe serum concentration of Amitriptyline can be increased when it is combined with Rilpivirine.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Amitriptyline.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amitriptyline.
RitodrineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ritodrine.
RitonavirThe serum concentration of Amitriptyline can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Amitriptyline can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Rizatriptan.
RolapitantThe serum concentration of Amitriptyline can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amitriptyline.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Amitriptyline.
RopiniroleAmitriptyline may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Amitriptyline can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amitriptyline.
RosiglitazoneThe metabolism of Amitriptyline can be decreased when combined with Rosiglitazone.
RotigotineAmitriptyline may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amitriptyline.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Amitriptyline.
SafrazineSafrazine may increase the serotonergic activities of Amitriptyline.
SalbutamolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Salbutamol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Amitriptyline.
SalmeterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Salmeterol.
SaquinavirThe serum concentration of Amitriptyline can be increased when it is combined with Saquinavir.
SaquinavirAmitriptyline may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Saxagliptin.
ScopolamineThe serum concentration of Amitriptyline can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amitriptyline.
SelegilineSelegiline may increase the serotonergic activities of Amitriptyline.
SelegilineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Amitriptyline.
SertindoleThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sertraline.
SertralineThe serum concentration of Amitriptyline can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amitriptyline.
SildenafilThe metabolism of Amitriptyline can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amitriptyline.
SiltuximabThe serum concentration of Amitriptyline can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Amitriptyline can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Amitriptyline can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Amitriptyline can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Amitriptyline.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Amitriptyline.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amitriptyline.
SotalolAmitriptyline may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Amitriptyline.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Amitriptyline.
SpiraprilThe serum concentration of Amitriptyline can be increased when it is combined with Spirapril.
SpironolactoneThe serum concentration of Amitriptyline can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Amitriptyline can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Amitriptyline can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Stiripentol.
StreptozocinThe serum concentration of Amitriptyline can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline.
SulfadiazineThe metabolism of Amitriptyline can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Amitriptyline can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Amitriptyline can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleAmitriptyline may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Amitriptyline can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sulpiride.
SumatriptanThe serum concentration of Amitriptyline can be increased when it is combined with Sumatriptan.
SumatriptanThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sumatriptan.
SunitinibThe serum concentration of Amitriptyline can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Suvorexant.
TacrineThe serum concentration of Amitriptyline can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Amitriptyline can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Amitriptyline.
TamoxifenThe serum concentration of Amitriptyline can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Amitriptyline.
TapentadolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Amitriptyline.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Amitriptyline.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Amitriptyline.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Amitriptyline can be increased when it is combined with Telaprevir.
TelavancinAmitriptyline may increase the QTc-prolonging activities of Telavancin.
TelithromycinAmitriptyline may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Amitriptyline can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Amitriptyline can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amitriptyline.
TemocaprilThe serum concentration of Amitriptyline can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Amitriptyline.
TenofovirThe metabolism of Amitriptyline can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Amitriptyline can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Amitriptyline can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Terbutaline.
TerfenadineThe serum concentration of Amitriptyline can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Amitriptyline can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Amitriptyline can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Amitriptyline can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Amitriptyline.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amitriptyline.
ThalidomideAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Amitriptyline.
TheophyllineThe metabolism of Amitriptyline can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amitriptyline.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amitriptyline.
ThioproperazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amitriptyline.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amitriptyline.
ThiorphanThe serum concentration of Amitriptyline can be increased when it is combined with Thiorphan.
ThiotepaThe metabolism of Amitriptyline can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Amitriptyline.
TiagabineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Amitriptyline.
TiclopidineThe metabolism of Amitriptyline can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Amitriptyline.
TimololThe serum concentration of Timolol can be increased when it is combined with Amitriptyline.
TipranavirThe serum concentration of Amitriptyline can be increased when it is combined with Tipranavir.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Amitriptyline.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Amitriptyline.
TocilizumabThe serum concentration of Amitriptyline can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Amitriptyline can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tolcapone.
ToloxatoneToloxatone may increase the serotonergic activities of Amitriptyline.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amitriptyline.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.
TopiramateThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amitriptyline.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Amitriptyline.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amitriptyline.
TrandolaprilThe serum concentration of Amitriptyline can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Amitriptyline.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the serotonergic activities of Amitriptyline.
TranylcypromineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Amitriptyline.
TrazodoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trazodone.
TrazodoneThe serum concentration of Amitriptyline can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amitriptyline.
TrifluoperazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trifluoperazine.
TrifluoperazineThe serum concentration of Amitriptyline can be increased when it is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Triflupromazine.
TriflupromazineThe serum concentration of Amitriptyline can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Amitriptyline can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Amitriptyline can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Triprolidine.
TroleandomycinThe serum concentration of Amitriptyline can be increased when it is combined with Troleandomycin.
UbenimexThe serum concentration of Amitriptyline can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Amitriptyline.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Amitriptyline.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amitriptyline.
ValsartanThe metabolism of Amitriptyline can be decreased when combined with Valsartan.
VandetanibAmitriptyline may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Amitriptyline.
VemurafenibThe serum concentration of Amitriptyline can be increased when it is combined with Vemurafenib.
VemurafenibAmitriptyline may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Amitriptyline can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Amitriptyline.
VerapamilThe metabolism of Amitriptyline can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Amitriptyline.
VigabatrinThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vilazodone.
VildagliptinThe serum concentration of Amitriptyline can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Amitriptyline can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Amitriptyline.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amitriptyline.
VincristineThe serum concentration of Amitriptyline can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Amitriptyline can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Amitriptyline.
VoriconazoleThe metabolism of Amitriptyline can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vortioxetine.
WarfarinAmitriptyline may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Amitriptyline can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Amitriptyline.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Amitriptyline.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Amitriptyline.
ZafirlukastThe metabolism of Amitriptyline can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amitriptyline.
ZiconotideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Amitriptyline.
ZimelidineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zimelidine.
ZimelidineThe serum concentration of Amitriptyline can be increased when it is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziprasidone.
ZiprasidoneThe metabolism of Amitriptyline can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Amitriptyline.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amitriptyline.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Amitriptyline.
ZonisamideThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amitriptyline.
ZotepineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Take with food to reduce irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Gould GG, Altamirano AV, Javors MA, Frazer A: A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry. 2006 Mar 1;59(5):408-14. Epub 2005 Sep 2. [PubMed:16140280 ]
  2. Troelsen KB, Nielsen EO, Mirza NR: Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl). 2005 Oct;181(4):741-50. Epub 2005 Sep 29. [PubMed:16032412 ]
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  4. Ushijima K, Sakaguchi H, Sato Y, To H, Koyanagi S, Higuchi S, Ohdo S: Chronopharmacological study of antidepressants in forced swimming test of mice. J Pharmacol Exp Ther. 2005 Nov;315(2):764-70. Epub 2005 Aug 3. [PubMed:16079297 ]
  5. Kalia M: Neurobiological basis of depression: an update. Metabolism. 2005 May;54(5 Suppl 1):24-7. [PubMed:15877309 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Onali P, Dedoni S, Olianas MC: Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther. 2010 Jan;332(1):255-65. doi: 10.1124/jpet.109.159939. Epub 2009 Oct 14. [PubMed:19828880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Onali P, Dedoni S, Olianas MC: Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther. 2010 Jan;332(1):255-65. doi: 10.1124/jpet.109.159939. Epub 2009 Oct 14. [PubMed:19828880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand, it can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 ...
Gene Name:
NTRK1
Uniprot ID:
P04629
Molecular Weight:
87496.465 Da
References
  1. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, Ye K: Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol. 2009 Jun 26;16(6):644-56. doi: 10.1016/j.chembiol.2009.05.010. [PubMed:19549602 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Receptor tyrosine kinase involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. Receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 which is less efficient in act...
Gene Name:
NTRK2
Uniprot ID:
Q16620
Molecular Weight:
91998.175 Da
References
  1. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, Ye K: Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol. 2009 Jun 26;16(6):644-56. doi: 10.1016/j.chembiol.2009.05.010. [PubMed:19549602 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Ozdogan UK, Lahdesmaki J, Mansikka H, Scheinin M: Loss of amitriptyline analgesia in alpha 2A-adrenoceptor deficient mice. Eur J Pharmacol. 2004 Feb 6;485(1-3):193-6. [PubMed:14757140 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic in...
Gene Name:
KCNQ2
Uniprot ID:
O43526
Molecular Weight:
95846.575 Da
References
  1. Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007 May;104(5):1256-64, tables of contents. [PubMed:17456683 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007 May;104(5):1256-64, tables of contents. [PubMed:17456683 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brain neurons (By similarity). This current is activated at membrane potentials that are below the threshold for action potentials. It regulates neuronal excitability, prolongs the latency before the firs...
Gene Name:
KCND2
Uniprot ID:
Q9NZV8
Molecular Weight:
70535.825 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated by interactions with other alpha subunits and with regulatory subunits.
Gene Name:
KCND3
Uniprot ID:
Q9UK17
Molecular Weight:
73450.53 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
blocker
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Angus JA, Black JW: Pharmacological assay of cardiac H2-receptor blockade by amitriptyline and lysergic acid diethylamide. Circ Res. 1980 Jun;46(6 Pt 2):I64-9. [PubMed:6103762 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF: Discovery of a novel member of the histamine receptor family. Mol Pharmacol. 2001 Mar;59(3):427-33. [PubMed:11179435 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
Functions in lipid transport from the endoplasmic reticulum and is involved in a wide array of cellular functions probably through regulation of the biogenesis of lipid microdomains at the plasma membrane. Involved in the regulation of different receptors it plays a role in BDNF signaling and EGF signaling. Also regulates ion channels like the potassium channel and could modulate neurotransmitt...
Gene Name:
SIGMAR1
Uniprot ID:
Q99720
Molecular Weight:
25127.52 Da
References
  1. Villard V, Meunier J, Chevallier N, Maurice T: Pharmacological interaction with the sigma1 (sigma1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci. 2011;115(3):279-92. [PubMed:21427517 ]
  2. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Di Matteo V, De Blasi A, Di Giulio C, Esposito E: Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci. 2001 May;22(5):229-32. [PubMed:11339973 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Wahlstrom A, Lenhammar L, Ask B, Rane A: Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation. Pharmacol Toxicol. 1994 Jul;75(1):23-7. [PubMed:7971731 ]
  2. Hamon M, Gozlan H, Bourgoin S, Benoliel JJ, Mauborgne A, Taquet H, Cesselin F, Mico JA: Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology. 1987 Jun;26(6):531-9. [PubMed:3037421 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW: Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996 Jan;66(1):47-56. [PubMed:8522988 ]
  2. Sebben M, Ansanay H, Bockaert J, Dumuis A: 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. Neuroreport. 1994 Dec 20;5(18):2553-7. [PubMed:7696602 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to sy...
Gene Name:
KCNQ3
Uniprot ID:
O43525
Molecular Weight:
96741.515 Da
References
  1. Punke MA, Friederich P: Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg. 2007 May;104(5):1256-64, tables of contents. [PubMed:17456683 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Components:
NameUniProt IDDetails
Beta-1 adrenergic receptorP08588 Details
Beta-2 adrenergic receptorP07550 Details
Beta-3 adrenergic receptorP13945 Details
References
  1. Werling LL, Keller A, Frank JG, Nuwayhid SJ: A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007 Oct;207(2):248-57. Epub 2007 Jun 30. [PubMed:17689532 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  3. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44. [PubMed:9131945 ]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  6. Website [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7. [PubMed:12228186 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44. [PubMed:9131945 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
  2. Ghahramani P, Ellis SW, Lennard MS, Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44. [PubMed:9131945 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. doi: 10.1016/j.cbi.2008.02.001. Epub 2008 Feb 14. [PubMed:18359012 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. [PubMed:11259560 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
  2. Banerjee T, Singh SK, Kishore N: Binding of naproxen and amitriptyline to bovine serum albumin: biophysical aspects. J Phys Chem B. 2006 Nov 30;110(47):24147-56. [PubMed:17125386 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Brinkschulte M, Breyer-Pfaff U: The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):61-6. [PubMed:6108517 ]
  2. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23